Aaron Luebke, MD
Hematology & Oncology · Bismarck, NDNPI 1699929281
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $637 of the $829 with a category attached, or 76.8%. It is spread thinly across 20 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $310, more than ten times the $14 reported in 2019.
Across 39 payments — averaging $21.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$191
- Lilly USA, LLC$132
- Eisai Inc.$65
- AbbVie$65
- Daiichi Sankyo Inc.$46
- AVEO Pharmaceuticals, Inc.$40
- plus $290 from 14 others
What the payments were for
- Food & beverage$63777%
- Education$19223%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 9 | $191 |
| Lilly USA, LLC | 2 | $132 |
| Eisai Inc. | 3 | $65 |
| AbbVie | 3 | $65 |
| Daiichi Sankyo Inc. | 3 | $46 |
| AVEO Pharmaceuticals, Inc. | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Puma Biotechnology, Inc. | 2 | $33 |
| Gilead(2 entities) | 2 | $28 |
| Octapharma USA, Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $20 |
| Merck | 1 | $20 |
| Coherus Oncology, Inc. | 1 | $20 |
| Foundation Medicine, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $14 |
| Novartis | 1 | $14 |
| Sanofi | 1 | $13 |
How this compares
$829 in reported general payments places this provider in the 55th percentile of 35 hematology & oncology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OjjaaraMomelotinib Dihydrochloride | 12 | $683,203 |
| LenvimaLenvatinib Mesylate | 25 | $606,817 |
| CalquenceAcalabrutinib Maleate | 34 | $433,561 |
| ErleadaApalutamide | 32 | $432,501 |
| AlecensaAlectinib Hcl | 21 | $382,810 |
| XtandiEnzalutamide | 28 | $271,016 |
| RevlimidLenalidomide | 20 | $207,754 |
| Lenalidomide | 11 | $169,549 |
| Abiraterone Acetate | 92 | $148,653 |
| ImbruvicaIbrutinib | 17 | $131,071 |
| Imatinib Mesylate | 49 | $90,926 |
| EliquisApixaban | 123 | $75,041 |
| OrgovyxRelugolix | 12 | $30,014 |
| CreonLipase/Protease/Amylase | 11 | $29,773 |
| Exemestane | 68 | $5,858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $65 | $606,81725 claims |
| Johnson & JohnsonErleada | $17 | $432,50132 claims |
| Astellas Pharma US IncXtandi | $20 | $271,01628 claims |
| PfizerEliquis | $191 | $75,041123 claims |
| AbbVieCreon | $65 | $29,77311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 35 hematology & oncology providers in North Dakota.
Other hematology & oncology in Bismarck
- Peter KurnialiBismarck$8K
- Matthew McGeeBismarck$3K
- Thandiwe GrayBismarck$2K
- Stewart SharpBismarck$2K
- Sagar RakshitBismarck$2K
- John ReynoldsBismarck$2K
- Alexander JohnsonBismarck$1K
- Edward WosBismarck$1K
- David Oladele-BankoleBismarck$16
- Baruti SerabeBismarck$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.